Direxion Daily MSCI South Korea Bull 3X Shares ETF logo

Direxion Daily MSCI South Korea Bull 3X Shares ETF (KORU)

Market Closed
5 Dec, 20:00
ARCA ARCA
$
158. 98
+11.24
+7.61%
$
130.63M Market Cap
0.1% Div Yield
93,332 Volume
$ 147.74
Previous Close
Day Range
156.54 161.69
Year Range
27.16 201.92
Want to track KORU and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Looking to Leverage Country ETFs? Here's 2 to Ponder

Looking to Leverage Country ETFs? Here's 2 to Ponder

Emerging market (EM) equities continue to be the benefactors of a weaker dollar, giving traders plenty of profitable opportunities in EM. Single-country ETFs are in play, with two traders may want to ponder: the Direxion Daily South Korea Bull 3X Shares (KORU) and the Direxion Daily MSCI Mexico Bull 3X Shares (MEXX).

Etftrends | 1 day ago
KORU: Navigating 2025 Volaility

KORU: Navigating 2025 Volaility

The Direxion Daily MSCI South Korea Bull 3X Shares aims for 300% daily returns of the MSCI Korea 25/50 Index but is risky as a long term hold. This ETF can yield significant gains during bull runs but can also incur substantial losses during downturns, as seen in Q4 2024. South Korea's stock market has rebounded from December lows but faces economic and political uncertainties, making short-term pullbacks likely.

Seekingalpha | 9 months ago
KORU Medical Systems Has A Long Runway

KORU Medical Systems Has A Long Runway

KORU Medical Systems' stock has surged 60% since November, driven by the success of its FREEDOM System for subcutaneous immunoglobulin delivery. The SCIg market is growing rapidly, with KORU outperforming competitors by capturing market share and benefiting from trends like prefilled syringes. Strong international growth, new therapies, and product innovations are key drivers, with significant revenue from recurring patients and promising future launches.

Seekingalpha | 9 months ago
Impressive Turnaround At KORU Medical

Impressive Turnaround At KORU Medical

KORU Medical Systems is poised for growth with solid revenue increases, multiple growth drivers, and a chance to reach cash flow breakeven in Q4. The FREEDOM system, designed for at-home drug delivery, offers recurring revenue from consumables and is gaining market share in the SCIg market. International expansion and novel therapies present significant growth opportunities, with international revenue growing 46% and novel therapies progressing to Phase 3 trials.

Seekingalpha | 1 year ago
South Korea Could Offer Traders Opportunities in EM

South Korea Could Offer Traders Opportunities in EM

Opportunities in China might be the first place to look for emerging market (EM) trade opportunities. But South Korea shouldn't be overlooked.

Etftrends | 1 year ago